IL6 and metabolic syndrome: There was a mixture of samples from each of the 4 clinical groups (controls, MetS, HD+ and HD- subjects) in both of the IL-6 response groups, suggesting that the ability of HDL to suppress IL-6 secretion in LPS-stimulated monocytes may not be directly linked to the clinical characteristics of the patient but rather, more likely, the composition of their HDL particles.